Evidence map›Paper›PMID 39710633›Full record

SynthesisBMC pulmonary medicine2024

The prognostic impact of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio on patients with small cell lung cancer receiving first-line platinum-based chemotherapy: a systematic review and meta-analysis.

Yuansheng Zhao, Yongsheng Wang, Yongquan Jiang, Jiandong Yang, Yuefen Zhang

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMC pulmonary medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yuansheng ZhaoDepartment of Cardiothoracic Surgery, Sinopharm TongMei General Hosptial, Datong, 037000, Shanxi Province, China.
Yongsheng WangDepartment of Cardiothoracic Surgery, Sinopharm TongMei General Hosptial, Datong, 037000, Shanxi Province, China.
Yongquan JiangDepartment of Cardiothoracic Surgery, Sinopharm TongMei General Hosptial, Datong, 037000, Shanxi Province, China.
Jiandong YangDepartment of Cardiothoracic Surgery, Sinopharm TongMei General Hosptial, Datong, 037000, Shanxi Province, China.
Yuefen ZhangDepartment of Medical Oncology, Sinopharm TongMei General Hosptial, 5999 HeRui Street, Hengan New District, Yungang District, Datong, 037000, Shanxi Province, China. zhangyuefen5999@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe prognostic significance of Neutrophil-to-Lymphocyte Ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) in Small Cell Lung Cancer (SCLC) patients receiving platinum-based chemotherapy is debated.

methodsThis study aims to elucidate their roles in survival outcomes. A systematic search across PubMed, Embase, Web of Science, and Cochrane Library identified relevant studies. The Newcastle-Ottawa Scale (NOS) evaluated study quality. Meta-analysis was conducted using random-effects and fixed-effects models, supplemented by sensitivity analysis.

resultsA total of 11 studies with 3,634 SCLC patients were included. Patients with high NLR had significantly decreased overall survival (OS) (HR = 1.39, 95% CI: 1.18-1.59, P < 0.001) and progression-free survival (PFS) (HR = 1.52, 95%CI: 1.27-1.78, P < 0.001). The OS was not statistically different between high and low PLR groups (HR = 1.13, 95%CI: 0.84-1.43, P = 0.265). Subgroup analysis revealed that OS in high NLR group was significantly lower across different strata, and OS in the high PLR group was significantly lower among patients with limited-stage SCLC (LS-SCLC) and populations with a PLR cutoff value < 160.

conclusionsHigh NLR is associated with poor OS and PFS in patients with SCLC receiving first-line platinum-based chemotherapy. PLR does not significantly impact OS, except in LS-SCLC patients and populations with a PLR cutoff value < 160. These findings require further validation from prospective studies.

Indexed as

Lung NeoplasmsLymphocytesNeutrophilsSmall Cell Lung CarcinomaAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBlood PlateletsHumansLymphocyte CountPlatelet CountPrognosisAntineoplastic AgentsFirst-line platinum-based chemotherapyMeta-analysisNeutrophil-to-lymphocyte ratioPlatelet-to-lymphocyte ratioPrognosisSmall cell lung cancer

Identifiers

PMID39710633
PMCPMC11665107

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.